Esmethadone (REL-1017) Improves Cognitive Function in Patients With Severe Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Post Hoc Analysis From a Phase 3 Randomized Controlled Trial

被引：0
|
作者：
Guidetti, Clotilde [1 ]
De Martin, Sara [1 ]
Pani, Luca [1 ]
Papakostas, George [1 ]
Pappagallo, Marco [1 ]
Serra, Giulia [1 ]
Apicella, Massimo [1 ]
Manfredi, Paolo [1 ]
Fava, Maurizio [1 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2024年 / 49卷
关键词：
NMDA Antagonists; Subjective Cognitive Impairment; Major Depressive Disorder (MDD);
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P169
引用
收藏
页码：160 / 161
页数：2
相关论文
共 26 条
  • [1] Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial
    Fava, Maurizio
    Stahl, Stephen M.
    Pani, Luca
    De Martin, Sara
    Cutler, Andrew J.
    Maletic, Vladimir
    Gorodetzky, Charles W.
    Vocci, Frank J.
    Sapienza, Frank L.
    Kosten, Thomas R.
    Kroeger, Cornelia
    Champasa, Paggard
    O'Gorman, Cedric
    Guidetti, Clotilde
    Alimonti, Andrea
    Comai, Stefano
    Mattarei, Andrea
    Folli, Franco
    Bushnell, David
    Traversa, Sergio
    Inturrisi, Charles E.
    Manfredi, Paolo L.
    Pappagallo, Marco
    JOURNAL OF CLINICAL PSYCHIATRY, 2024, 85 (03)
  • [2] REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial
    Fava, Maurizio
    Stahl, Stephen
    Pani, Luca
    De Martin, Sara
    Pappagallo, Marco
    Guidetti, Clotilde
    Alimonti, Andrea
    Bettini, Ezio
    Mangano, Richard M.
    Wessel, Thomas
    de Somer, Marc
    Caron, Judy
    Vitolo, Ottavio V.
    DiGuglielmo, Gina R.
    Gilbert, Adam
    Mehta, Hiren
    Kearney, Morgan
    Mattarei, Andrea
    Gentilucci, Marco
    Folli, Franco
    Traversa, Sergio
    Inturrisi, Charles E.
    Manfredi, Paolo L.
    AMERICAN JOURNAL OF PSYCHIATRY, 2022, 179 (02): : 122 - 131
  • [3] REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial (vol 179, pg 122, 2022)
    Fava, Maurizio
    AMERICAN JOURNAL OF PSYCHIATRY, 2022, 179 (02): : 131 - 131
  • [4] Depression Severity and Efficacy Outcomes: Post Hoc Analyses From a Phase 3 Trial of the Novel NMDAR Antagonist Antidepressant, Esmethadone, for the Adjunctive Treatment for MDD With Inadequate Response to Standard Antidepressants
    Fava, Maurizio
    Pani, Luca
    De Martin, Sara
    Kroeger, Cornelia
    Champasa, Paggard
    Guidetti, Clotilde
    Comai, Stefano
    Matterei, Andrea
    Folli, Franco
    Traversa, Sergio
    Gorodetsky, Charles
    Vocci, Frank
    Sapienza, Frank
    Kosten, Thomas
    Inturrisi, Charles
    Bushnell, David
    Kappler, Martin
    Manfredi, Paolo
    Pappagallo, Marco
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 197 - 197
  • [5] Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants
    Thase, Michael E.
    Youakim, James M.
    Skuban, Aleksandar
    Hobart, Mary
    Augustine, Carole
    Zhang, Peter
    McQuade, Robert D.
    Carson, William H.
    Nyilas, Margaretta
    Sanchez, Raymond
    Eriksson, Hans
    JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (09) : 1224 - +
  • [6] Effects of Levomilnacipran ER on Cognition and Functioning in Patients with Major Depressive Disorder: Post Hoc Analysis of a Phase 3 Trial
    Harvey, Philip
    Gommoll, Carl
    Chen, Changzheng
    Lipschutz, Alan
    Wesnes, Keith
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S361 - S362
  • [7] Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study
    Thase, Michael E.
    Youakim, James M.
    Skuban, Aleksandar
    Hobart, Mary
    Zhang, Peter
    McQuade, Robert D.
    Nyilas, Margaretta
    Carson, William H.
    Sanchez, Raymond
    Eriksson, Hans
    JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (09) : 1232 - +
  • [8] Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial
    Kosten, Thomas
    Aharonovich, Efrat
    Nangia, Narinder
    Zavod, Abigail
    Akerman, Sarah C.
    Lopez-Bresnahan, Maria
    Sullivan, Maria A.
    ADDICTIVE BEHAVIORS, 2020, 111
  • [9] Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study
    Kato, Masaki
    Shiosakai, Masako
    Kuwahara, Kazuo
    Iba, Katsuhiro
    Shimada, Yuki
    Saito, Mizuki
    Isogai, Yuki
    Sekine, Daisuke
    Aoki, Kazuo
    Koga, Nobuyuki
    Higuchi, Teruhiko
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2024, 78 (02) : 113 - 122
  • [10] Routinely accessible parameters of mineralocorticoid receptor function, depression subtypes and response prediction: a post-hoc analysis from the early medication change trial in major depressive disorder
    Engelmann, Jan
    Murck, Harald
    Wagner, Stefanie
    Zillich, Lea
    Streit, Fabian
    Herzog, David P.
    Braus, Dieter F.
    Tadic, Andre
    Lieb, Klaus
    Muller, Marianne B.
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2022, 23 (08): : 631 - 642
123